TEAM Study: Positive Airway Pressure for Mucus Plugs in Asthma and COPD
This study is looking at whether using positive pressure during breathing helps a medication called n-acetylcysteine (NAC) better reach and break down mucus plugs in the lungs of people with asthma or COPD. NAC is a mucolytic drug (helps clear mucus), and albuterol is a bronchodilator (helps open airways). The study will compare delivering NAC with a standard nebulizer to delivering it with the AeroEclipse-VersaPAP System, which adds positive pressure during inhalation. Researchers want to see if this positive pressure delivery reduces mucus plugs and improves lung function. You can join if you are 18-85 years old and have asthma or COPD. The study plans to enroll 40 participants.
- Study design
- This interventional study plans to enroll 40 participants. You will be assigned to one of two groups: NAC with a jet nebulizer or NAC with the AeroEclipse-VersaPAP nebulizer.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will measure changes in mucus plug scores from one week before treatment to one week after treatment, over an average of six weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- John Fahy, MD, MS · PRINCIPAL_INVESTIGATOR · Professor of Medicine
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Change in mucus plug score1 week before treatment to 1 week post treatment, an average of 6 weeks
The primary outcome is the % change in mucus plug score from 1 week before treatment to 1 week post treatment.